PGG glucan - Biothera

Drug Profile

PGG glucan - Biothera

Alternative Names: B-glucan PGG; BTH-1677; Imprime PGG; Soluble beta glucan - Biothera

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biothera
  • Developer Biothera; Dana-Farber Cancer Institute; Mayo Clinic; Merck
  • Class Antibacterials; Antineoplastics; Beta Glucans
  • Mechanism of Action Fc gamma receptor IIA modulators; Immunostimulants; Macrophage 1 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Colorectal cancer
  • Phase II Breast cancer; Head and neck cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer
  • Phase I/II Chronic lymphocytic leukaemia
  • Research Follicular lymphoma
  • Suspended Infections
  • No development reported Pancreatic cancer
  • Discontinued Myelosuppression; Stem cell mobilisation

Most Recent Events

  • 28 Nov 2017 Biothera enters into an agreement with Genentech for a phase Ib/II trial in Colorectal cancer (Combination therapy, Metastatic disease)
  • 20 Nov 2017 Discontinued - Phase-I/II for Stem cell mobilisation (In volunteers) in USA (IV) (Biothera Pipeline, November 2017)
  • 20 Nov 2017 Discontinued - Preclinical for Myelosuppression in USA (IV) (Biothera Pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top